Evidence map›Paper›PMID 39811103›Full record

ArticleEuropean urology open science2025

Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer.

Madison T Baxter, Christopher C Conlin, Aditya Bagrodia, Tristan Barrett, Hauke Bartsch, Anja Brau, Matthew Cooperberg, Anders M Dale, Arnaud Guidon, Michael E Hahn and 17 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06579417 (Advanced Restriction Imaging and Reconstruction Technology for Prostate MRI), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06579417 recruitingnot on this map

Advanced Restriction Imaging and Reconstruction Technology for Prostate MRI (ART-Pro)

TypeobservationalSponsorUniversity of California, San DiegoRan2023 to 2029Enrolled500ConditionsProstate CancerArmsRSI MRI
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Madison T BaxterDepartment of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA, USA.
Christopher C ConlinDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Aditya BagrodiaDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Tristan BarrettDepartment of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Hauke BartschDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Anja BrauGE Healthcare, Chicago, IL, USA.
Matthew CooperbergDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Anders M DaleDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Arnaud GuidonGE Healthcare, Chicago, IL, USA.
Michael E HahnDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Mukesh G HarisinghaniDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Juan F Javier-DesLogesDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Sophia C KamranDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Christopher J KaneDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Joshua M KupermanDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Daniel J A MargolisDepartment of Radiology, Weill Cornell Medical College, New York, NY, USA.
Paul M MurphyDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Nabih NakrourDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Michael A OhligerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Rebecca Rakow-PennerDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Ahmed ShabaikDepartment of Pathology, UC San Diego School of Medicine, La Jolla, CA, USA.
Jeffry P SimkoDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Clare M TempanyDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Natasha WehrliDepartment of Radiology, Weill Cornell Medical College, New York, NY, USA.
Sean A WoolenDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Jingjing ZouDepartment of Biostatistics, Herbert Wertheim School of Public Health & Human Longevity Science, University of California San Diego, La Jolla, CA, USA.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric magnetic resonance imaging (bpMRI) and advanced, quantitative magnetic resonance imaging (MRI) techniques. One such advanced technique is the Restriction Spectrum Imaging restriction score (RSIrs), an imaging biomarker that has been shown to improve quantitative accuracy of patient-level csPCa detection. Advanced Restriction imaging and reconstruction Technology for Prostate MRI (ART-Pro) is a multisite, multinational trial that aims to evaluate whether IV contrast can be avoided in the setting of standardized, state-of-the-art image acquisition, with or without addition of RSIrs. Additionally, RSIrs will be evaluated as a stand-alone, quantitative, objective biomarker. ART-Pro will be conducted in two stages and will include a total of 500 patients referred for multiparametric prostate MRI with a clinical suspicion of prostate cancer at the participating sites. ART-Pro-1 will evaluate bpMRI, mpMRI, and RSIrs on the accuracy of expert radiologists' detection of csPCa and will evaluate RSIrs as a stand-alone, quantitative, objective biomarker. ART-Pro-2 will evaluate the same MRI techniques on the accuracy of nonexpert radiologists' detection of csPCa, and findings will be evaluated against the expertly created dataset from ART-Pro-1. The primary endpoint is to evaluate whether bpMRI is noninferior to mpMRI among expert (ART-Pro-1) and nonexpert (ART-Pro-2) radiologists for the detection of grade group ≥2 csPCa. This trial is registered in the US National Library of Medicine Trial Registry (NCT number: NCT06579417) at ClinicalTrials.gov. Patient accrual at the first site (UC San Diego) began in December 2023. Initial results are anticipated by the end of 2026.

Indexed as

Biparametric magnetic resonance imagingClinical trialMultiparametric magnetic resonance imagingProstate cancerRestriction Spectrum ImagingRestriction Spectrum Imaging restriction score

Identifiers

PMID39811103
PMCPMC11730575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.